{
    "clinical_study": {
        "@rank": "15044", 
        "arm_group": [
            {
                "arm_group_label": "Fludarabine", 
                "arm_group_type": "Experimental", 
                "description": "The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously."
            }, 
            {
                "arm_group_label": "HD-Arac", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether Fludarabine in  combination with cytarabine\n      is more effective than high-dose cytarabine in post-remission therapy for patients with\n      AML1-ETO acute myeloid leukemia."
        }, 
        "brief_title": "AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "AML1-ETO Fusion Protein Expression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical and laboratory diagnosis of AML1-ETO positive acute myeloid leukemia\n\n          -  In status of complete remission after one to two courses of induction therapy with\n             DA(Daunorubicin 60mg/m2/d for 3 days, cytarabine 100mg/m2/d for 5-7days) regimen\n\n          -  ECOG (Eastern Cooperative Oncology Group)  score: <2\n\n        Exclusion Criteria:\n\n          -  Serious liver/ kidney dysfunction\n\n          -  Cardiac function level: 2 above\n\n          -  Female in  pregnancy or lactation\n\n          -  With serious infection diseases or other diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024308", 
            "org_study_id": "CHXY-AML01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fludarabine", 
                "description": "50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }, 
            {
                "arm_group_label": [
                    "Fludarabine", 
                    "HD-Arac"
                ], 
                "description": "2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug", 
                "other_name": "Cytosar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Fludarabine monophosphate", 
                "Vidarabine", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute myeloid leukemia,", 
            "AML1-ETO fusion protein,", 
            "Fludarabine,", 
            "recurrence"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "contact": {
                "email": "shongxm@gmail.com", 
                "last_name": "Xianmin Song", 
                "phone": "86-21-31161285"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200433"
                }, 
                "name": "Department of Hematology, Changhai Hospital"
            }, 
            "investigator": {
                "last_name": "Xianmin Song", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "shongxm@gmail.com", 
            "last_name": "Xianmin Song, Doctor", 
            "phone": "83-21-31161285"
        }, 
        "overall_official": {
            "affiliation": "Department of Hematology, Changhai Hospital", 
            "last_name": "Xianmin Song, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of participants with disease recurrence", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024308"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Changhai Hospital", 
            "investigator_full_name": "Xianmin Song", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of Participants in survival", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Changhai Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Changhai Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}